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Abstract: This work investigated the preparation of chitosan nanoparticles used as carriers for
doxorubicin for targeted cancer delivery. Prepared nanocarriers were stabilized and functionalized via
zinc ions incorporated into the chitosan nanoparticle backbone. We took the advantage of high expression
of sarcosine in the prostate cancer cells. The prostate cancer targeting was mediated by the AntiSar
antibodies decorated surface of the nanocage. Formation of the chitosan nanoparticles was determined
using a ninhydrin assay and differential pulse voltammetry. Obtained results showed the strong effect
of tripolyphosphine on the nanoparticle formation. The zinc ions affected strong chitosan backbone
coiling both in inner and outer chitosan nanoparticle structure. Zinc electrochemical signal depended
on the level of the complex formation and the potential shift from −960 to −950 mV. Formed complex
is suitable for doxorubicin delivery. It was observed the 20% entrapment efficiency of doxorubicin
and strong dependence of drug release after 120 min in the blood environment. The functionality of
the designed nanotransporter was proven. The purposed determination showed linear dependence in
the concentration range of Anti-sarcosine IgG labeled gold nanoparticles from 0 to 1000 µg/mL and
the regression equation was found to be y = 3.8x − 66.7 and R2 = 0.99. Performed ELISA confirmed
the ability of Anti-sarcosine IgG labeled chitosan nanoparticles with loaded doxorubicin to bind to the
sarcosine molecule. Observed hemolytic activity of the nanotransporter was 40%. Inhibition activity
of our proposed nanotransporter was evaluated to be 0% on the experimental model of S. cerevisiae.
Anti-sarcosine IgG labeled chitosan nanoparticles, with loaded doxorubicin stabilized by Zn ions, are a
perspective type of nanocarrier for targeted drug therapy managed by specific interaction with sarcosine
and metallothionein for prostate cancer.
Keywords: doxorubicin; chitosan; zinc; sarcosine; ninhydrin; prostate cancer; peroxidase activity;
gold nanoparticle; magnetic gold nanoparticle
1. Introduction
The use of biodegradable polymeric nanoparticles (NPs) for controlled drug delivery has shown
significant therapeutic potential in several cancer diseases. One of the most utilized biopolymer is chitosan
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(CS) due to its beneficial chemical-physical properties [1]. Previous studies reported its antioxidant [2],
anti-hypertensive [3], anti-diabetic, anti-obesity [4], neuroprotective [5] and bacteriostatic effects [6].
Moreover, chitosan plays an important role in the cell regulation and tissue regeneration [7,8]. From the
chemical point of view, chitosan is a weak base polysaccharide with high amino-group density per
disaccharide unit. In the dependence on pH of environment the amino groups ensure diverse molecular
behavior. Generally, acidic pH causes protonation of amino-groups and positive charge. Simultaneously,
the chitosan solubility increases when decreasing the value of pH [9].
The ability of chitosan gelation and crosslinking has been observed with several compounds.
Protocols that employed aldehydes (e.g., glutaraldehyde) and acids (e.g., thioglycolic, acrylic and
oxalic acid) can be found in the literature [10]. Ionic cross-links lead to nanoparticle formation
which could be reached by electrostatic interaction with phosphoric acid derivatives such as sodium
tripolyphosphate penta basic (TPP) which is a nontoxic, anionic chelating agent [11]. Chitosan’s ability
of quick gelling on contact with TPP relies on the formation of inter- and intramolecular cross-linkages
between TPP phosphates and chitosan amino groups. It was found out that the size and size
distribution of the chitosan–TPP nanoparticles depends on concentration, molecular weight and
conditions of mixing, i.e., stirring or sonication [12]. Gan et al. focused on the influence of TPP
ratio: CS and pH on nanoparticle size and ξ-potential. The main results show the higher CS
concentration and higher pH caused bigger particle size (in the range 140–180 nm based on the
CS molecular weight) and increasing trend of ξ-potential from 30 to 50 mV. Authors explained this
phenomenon by particle aggregation, rather than by further growth of the individual particle size after
initial formation [13]. Complex information of CS–TPP interactions could provide circular dichroism
spectroscopy [14], infra-red spectroscopy [15] or SEM/TEM techniques for size and morphology [16].
Colorimetric methods allow the study of chitosan interactions indirectly—e.g., ninhydrin assay,
Cibacron Brilliant Red [17] or one-step depolymerization with sodium nitrite followed by the reaction
of the end product with thiobarbituric acid [18].
The positive charge of CS NPs enables to bind negative charged biomolecules via electrostatic
interaction. These properties have been used in several studies focused on several delivery systems
including drugs, genes or nanoparticle delivery to the target tissues which is well described in many
reviews [19–24]. Lee et al. demonstrated the chemical conjugation of CD7− specific single-chain
antibody on the CS nanoparticle backbone useful for the delivery of siRNA into CD4+ T cell lines [25].
Generally, monoclonal antibodies are clinically established therapeutics and presents perspective
strategy emerging to target them for more effective treatment of cancer [26]. Tumor tissue is
characterized by different metabolism, higher expression of specific biomolecules and changed
morphology. In 2009 Sreekumar published a crucial article about potential role of sarcosine in
the prostate cancer. Metabolomic profiling of prostate cancer (PC) progression identified markedly
elevated levels of sarcosine (N-methyl glycine) in metastatic PC and modest but significant elevation
of the metabolite in tissue and urine [27]. Moreover, sarcosine higher levels have been confirmed in
thyroid [28] and breast cancer [29].
Many studies also indicate higher expression of metallothionein (MT) in the case of prostate
cancer [30]. MT belongs to a family of low molecular weight proteins that are involved in zinc and
redox metabolism as well as in many aspects of cancer biology and resistance to many toxic drugs [31].
In our previous published work, we have shown significant increases of MT in malignant tumors [32].
Moreover, the higher zinc uptake by tumor tissue has been noted [33].
Although, the progression of the cancer disease therapy has been given, the importance of finding the
effective cancer treatment approach is still the main field of many researchers. The aim of our study was to
design a chitosan based nanotransporter for anticancer drugs doxorubicin. We assumed the positive effect
of zinc ions in the nanoparticle structure for its stability, target effect to MT, specific interaction with AntiSar
antibody and increased uptake of the nanotransporter from the bloodstream (Figure 1). Direct targeting
for prostate cancer ensures the presence of AntiSar antibodies. Function and stability of our designed
nanotransporter was investigated by the spectrophotometric and electrochemical approaches.
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Figure 1. (A) Schematic diagram of the effect of chitosan nanoparticles for the complex of zinc,
doxorubicin and specific antibodies. Tumor tissue is acidic environment (pH 5–7), which leads to
destabilization of the NP structure and drug release. Chitosan nanoparticles are modified by an
antibody specific to tumor-associated molecules. In a healthy tissue, a nanotransporter penetrates but
the destabilization of the nanotransporter is limited. Healthy cells do not express the tumor antigen and
metallothionein, the protein of the molecule and thus there is no targeted binding on the cell surface.
(B) Scheme of CS-Zn-AntiSar nanoparticles formation for doxorubicin delivery to prostate tumor cells.
2. Results
2.1. Biophysical Characterization of CS Nanoparticles
For characterization of the formed nanoparticles and the influence of zinc ions and
TPP on nanoparticles formation spectrophotometric analysis and electrochemistry have been
used. While electrochemistry provide data about zinc availability in the nanoparticle structure,
the spectrophotometric analysis is based on the reaction of CS with ninhydrin solution which is enabled
to react with primary and secondary amino groups. The chromophore is created by amine condensation
with a molecule of ninhydrin to give Ruhemann purple (Figure 2A). From absorbance spectra (Figure 2B)
of ninhydrin-CS complex three characteristic absorbance maxima in (a) 342, (b) 408 and (c) 572 nm are
obvious. While absorbance maximum A408 and A572 corresponds to the Rhueman purple complex the
linear relationship with the CS concentration has been observed. The absorbance peak at 342 nm appears
when the CS-ninhydrin reaction is stopped by aqueous ethanol solution [34].
2.1.1. Ninhydrin Assay Optimization
Firstly, the effects of several factors including the reaction temperature, reaction time and
the ninhydrin concentration on the chitosan-ninhydrin reaction were investigated to optimize the
specificity and sensitivity. Figure 2C shows the dependence of reaction temperature 70, 80, 90 and
100 ◦C where is obvious the increase of chromophore absorbance in correlation with higher temperature
in both absorbance maximum A408 and A572. The reaction temperature was set on 100 ◦C for testing
the reaction time (0, 10, 20, 30, 40, 50, 60 min). The results (Figure 2D) clearly shown the reaction time
up to 40 min leads to the highest absorbance which is stable after 50 and 60 min at A408 and A572.
The dependence of ninhydrin amount entering the reaction with chitosan was investigated. Figure 2E
shows an increasing trend of signal in correlation with the increasing ninhydrin amount up to 32 µg
per reaction. Higher concentration caused slight decrease of the signal both in A408 and A572. We chose
the optimal conditions of ninhydrin assay for chitosan detection (100 ◦C reaction temperature, 40 min
reaction time and 32 µg on ninhydrin per reaction) to test ninhydrin assay reproducibility. In the
Figure 2F absorbance spectra present 4 times repetition of the analysis and added inset illustrates each
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measurement of absorbance maximum at A408 and A572. The calculated relative standard deviation is
2% (Table 1). The dependence of chitosan concentration (0–0.5 mg/mL) on absorbance A408 and A572
is shown in Figure 2G,H respectively. Calculated limit of detection was 2 µg/mL for A408 and A572.
Other analytical parameters such as LOD, LOQ, Linear range are summarized in Table 1.
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Biophysical characterization of S . (A) The principle of i rin ti
(B) Absorbance spectra of ninhydrin-CS complex (CS concentration 0–0.5 mg/mL), ninhydrin
reagent and 1% acetic acid. Optimization of the method: (C) reaction temperature (70, 80, 90, 10 ◦C).
(D) reaction tim (0, 10, 20, 30, 40, 50, 60 min) (E) ninhydrin amount per reaction (12, 16, 20, 24, 28,
32, 36, 40 µg). (F) Reproducibility of assay pre ented as absorb nce spe tra and the slope of each
v lue in A408 nm and A572 nm (n = 5). Dependence of CS oncentrati (0–0.6 mg/mL) on absorbance
(G) A408 nm. (H) A573 nm, 3 times repeated. The measurement conditions for all samples were:
ninhydrin amount per reaction 32 µg, CS concentration 0.25 mg/mL, reaction time 40 min and reaction
temperature 100 ◦C unless noted otherwise.
i
Substance Regression Equation Linear Dynamic Range (µg/mL) R2 LOD (µg/mL) LOQ (µg/mL) RSD * (%)
Chitosan 408 1.7469x + .1037 8–500 0.9 65 17
Chitosan A572 y = 1.5443x + 0.0384 8–500 0.9969 2 19 2
* n = 5.
2.1.2. Characterization of Zn-TPP-CS Nanoparticles Using Ninhydrin Assay
We used ninhydrin assay to monitor chitosan properties in the presence of TPP and zinc ions.
As was described in the introduction, TPP as well as zinc ions stabilize chitosan crosslinked structure
and provide nanoparticle formation. The scheme in Figure 3A demonstrates the principle of use
ninhydrin assay to characterize CS nanoparticles. The relaxed structure of chitosan (a) has an accessible
amino group for ninhydrin reaction. While the TPP is added (b) the structure is strongly crosslinked
and the nanoparticles are formed. The number of accessible amino groups decreases proportionally
with the level of crosslinking and the structure of formed nanoparticles. This behavior results to less
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accessible amino groups which cause the lower absorbance signal of ninhydrin [35,36]. Zinc ions could
be added in two ways. Firstly, the zinc is added before TPP reaction with chitosan. In this case could
be assumed, the zinc ions stabilize the inner structure (c) of chitosan NP whereas the zinc ions added
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Figure 3. Spectrophotometrical characterization of CS NPs. (A) Characterization of Zn-TPP-CS
nanoparticles using ninhydrin assay. The relaxed CS has accessible NH2 groups for ninhydrin reaction.
TPP and Zn caused crosslinking affecting the structure stabilization and decreasing signal intensity.
T o types of Ps have been designed: Zn inner type (I) and Zn outer type (II). The effect of changing
concentration of each component of NPs has been observed using the ninhydrin assay. The signal of
CS itself is interposed to the sample absorbance (light blue and red lines): (B) zinc (0.02, 0.03, 0.06, 0.13,
0.25, 0.50 mg/ L), (C) TPP (0.13, 0.25, 0.50, 1.00 2.00, 4.00 mg/ L), (D) CS (0.06, 0.13, 0.25, 0.50, 1.00,
2.00 mg/ L) and 2.00 mg/ L TPP, (E) TPP (0.13, 0.25, 0.50, 1. 0, 2.00, 4.00 mg/mL) and 2.00 mg/mL
CS. (F) Inner type (I): CS (0.06–2 mg/mL) with Zn (0.5 mg/mL), addition of TPP (2 mg/mL), (G) Outer
type (II): CS (0.06, 0.13, 0.25, 0.50, 1. 0, 2. 0 mg/mL) with TPP (2 mg/mL), addition of Zn (0.50 mg/mL).
(H) Inner type (I): Zn (0.02, 0.03, 0.06, 0.13, 0.25, 0.5 mg/mL) with CS (2 mg/mL), addition of TPP
(2 mg/mL). (I) Outer type (I): TPP (2 mg/mL) with CS (2 mg/mL), addition of Zn (0.02, 0.03, 0.06, 0.13,
0.25, 0.50 mg/mL). Further details are described in Figure 2 and Materials and Methods section.
Firstly, we wanted to exclude interaction of zinc or TPP with ninhydrin. From the Figure 3B,C
is obvious the equal signal intensity for all applied concentrations comparable to ninhydrin signal
intensity in both A408 and A572. In order to see the influence of TPP and zinc on the crosslinking effect,
the results are interleaved by the signal of chitosan alone (A408 light blue curve and A572 light red
curve). The greater the difference in signal, the greater the crosslinking effect was estimated. Figure 3D
is shows the dependence of CS concentrations from 0.06 to 2.00 mg/mL in the presence of 2 mg/mL
TPP. The low CS concentration in the presence of TPP shows similar signal intensity as CS alone.
From 0 to 0.5 mg/mL is evident that the signal intensity is lower than CS alone. The CS NPs are well
formed in the concentration 2 mg/mL of CS and the higher TPP concentration caused its stabilization.
From Figure 3E the apparent signal intensity of CS NPs decreases at higher TPP concentration that
results to more crosslinked structure. Further results are focused on comparison of inner and outer
type of NPs stabilized by zinc ions. In the case of Zn-inner type of NPs, zinc ions are inside the CS
structure and in the case of outer type of NPs, the zinc on the NPs surface. Both types are the result of
the different preparation protocol described in the materials and methods caption. Figure 3F (inner
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type) and Figure 3G (outer type) shows similar trend of signal intensity in the dependence of CS
concentration. In this case we can assume that the applied CS concentration did not influence the
stability of the NP. Interestingly, higher effect to NPs formation shows zinc ions addition. In both cases
(Figure 3I), the zinc addition (from 0.02 to 0.5 mg/mL) caused signal intensity decrease in comparison
with the CS itself, which indicates that the structure is more closed and stabilized. In addition, the zinc
ions addition before TPP crosslinking shows higher efficiency of Zn-CS NPs stabilization (Figure 3H)
which results in an overall lower signal of NPs compared to CS (2 mg/mL).
2.1.3. Electrochemical Study of CS NPs Formation
The dependence of zinc concentration (from 0 to 2 mg/mL) on the electrochemical signal is shown
in Figure 4A(a). In the case of zinc-TPP interaction, the potential shift is the same as well as zinc alone
−1.017 V. However, the electrochemical response increases with the concentration of zinc ions. When the
Zn2+ concentration increases from 0.06 mg/L to 1 mg/mL the electrochemical response decreases in two
folds compared to Zn2+ alone (Figure 4A(b)). In another variant, to the 2 mg/mL CS was added zinc
ions in the concentrations 0.02, 0.03, 0.06, 0.13, 0.25, 0.50 mg/mL). The graph Figure 4A(c) shows rapid
decrease of zinc electrochemical signal. This effect could be caused by CS adsorption on the electrode
surface. The difference is clearly shown in the zinc peak potential shift followed by increasing zinc
concentration (Figure 4A(c)). Finally, the same method was used for the determination of CS and TPP
interactions. Summarized results showed the weak electrochemical signal (in order of units of nA) and
the influence of CS on decreasing the electrochemical signal (Figure 4A(d)).
We used electrochemistry to investigate the behavior of the CS nanotransporter and influence
of zinc ions to stabilize its structure outside and inside the transporter. In the inner type of CS
NP, the zinc was added before TPP crosslinking whereas the outer type is characterized by the
presence of zinc ions on the nanoparticle surface due to the zinc addition after the TPP gelation process.
Figure 4B(a) shows the influence of increasing CS concentration (0.06, 0.13, 0.25, 0.50, 1.00, 2.00 mg/mL)
on zinc (0.50 mg/mL) signal which exhibit decreasing dependence in the case of Zn inner type of
nanotransporter. Monitored peak potential was in the range from −960 to −950 mV, that means good
agreement with the inner type of CS NPs. Although, the increased CS concentration correlated with
the electrochemical signal in both inner and outer type of zinc stabilized nanotransporter, the higher
electrochemical signal is observed in the case of outer type (Figure 4B(b)). These results confirmed the
zinc stabilization function on the nanoparticle surface. More prominent differences can be seen after
subtraction of both electrochemical signals. Figure 4B(b,c) shows an apparent difference between each
type of the nanotransporter. The increasing CS concentration (0.06, 0.13, 0.25, 0.50, 1.00, 2.00 mg/mL)
causes higher difference up to 0.12 mg/mL followed by strong difference decrease. In addition,
the influence of zinc ions concentration (0.02, 0.03, 0.06, 0.13, 0.25, 0.50 mg/mL) was studied in
the dependence of electrochemical behavior of CS NPs transporter. In both cases, the increasing
of zinc concentration caused higher electrochemical signal of zinc ions and the peak potential shift.
The outer type of zinc ions stabilized the nanotransporter, showing the higher electrochemical response
(Figure 4B(b,d,f)). Data was expressed as a difference of the inner type and outer type nanotransporter
electrochemical signal on the Figure 4B(f). The apparent increase of the electrochemical signal in the
concentration of zinc ions ranges from 0.06 to 1.00 mg/mL. This range expresses the weaker influence
of CS to decrease the electrochemical signal. At higher zinc concentrations, there is a reduction in the
difference between inner and outer type of Zn/CS NPs due to the fact that nanoparticles are unable to
bind more zinc into its structure.
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2.2. Doxorubicin Encapsulation to the CS NPs Structure
The described CS nanotransporter is primarily designed for drug delivery to target cancer tissue.
For this purpose, doxorubicin was tested as one of the most used medicines for cancer diseases.
To eliminate the influence of the doxorubicin ninhydrin test—which is one of four basic approaches to
the characterization of Zn/CS NPs—the effect of encapsulated doxorubicin on the spectrophotometric
signal of Ruhemann’s purple was investigated. Graphs in Figure 5A show the dependence of doxorubicin
addition (0, 2, 3, 6, 13, 25, 50, 100µM) on the absorbance at 408 nm (a) and 572 nm (b) which is characteristic
absorbance maxima of the Ruhemann’s purple. Given values are recalculated as 100 percent absorbance
of CS-ninhydrin product without Dox. Obtained data of both signals show the variability from 5 to
10%. These results indicate the formed complex is stable and the doxorubicin has no effect on Zn/CS
NPs stabilization.
In order to monitor the drug release from the nanotransporter, the further manipulation with the
nanotransporter to purify it from the unbound parts of the complex was mediated via gold magnetic
nanoparticles (AuMNPs). AuMPs could easily be encapsulated inside the NPs cage before adding
the crosslinking agent. A maghemite core gives the nanoparticles magnetic properties and the gold
Nanomaterials 2017, 7, 435 8 of 22
layer on the surface mediates interactions with amino groups of CS. A brief scheme of the AuMNPs
enclosing the structure of Zn/CS NPs/Dox-AuMNPs is shown in the Figure 5B(a). Magnetic Zn/CS
nanoparticles are immobilized via external magnet and the unbounded parts of the mixture could be
washed. The described system was used for the encapsulation efficiency evaluation. TPP was added
in various concentrations to the Zn/CS mixture. After the crosslinking process, the magnetic Zn/CS
NPs/Dox was transferred to the fresh buffer (10 mM phosphate buffer, pH 5) and the fluorescence
of the doxorubicin was measured. Figure 5B(b) illustrates a decreasing trend of the doxorubicin
fluorescence with the higher concentration of TPP. This could be attributed to the stronger crosslinking
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analysis were  tested.  The  ability  of AuNPs  aggregation which  is  visible  as  a  purple  dot  on  the 
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Figure 3 and Materials and Methods section.
Doxorubicin carried by Zn/CS NPs can be released through degradation of polymeric surface,
leading to a clear release effect. It has been described that drug release of CS based carriers depends
on the external conditions such as temperature, ionic strange, matrix composition and pH of the
environment [37]. Study of release mechanisms of nanoparticle cargo is one of the basic aspects of
NPs characterization. The Zn/CS NPs stability and doxorubicin release at intervals of several hours to
several days was investigated [38]. Zn/CS NPs were subjected for 28 h to doxorubicin fluorescence
sensing and the cumulative released amount of Dox was calculated. Figure 5C presents the obtained
dependence of time on cumulative doxorubicin release amount in selected environment conditions:
blood, phosphate buffers (10 mM) pH 5, 7 and 8. Results clearly show the rapid Dox release began
immediately and ends after 250 min. Further Dox release is not intensive and the NPs are stable.
An obvious difference between each environment shows the highest stability of Zn/CS NPs in pH 5 and
7. The strongest cumulative released of Dox amount is observed in the blood environment. The binding
affinity of CS/NPs on erythrocytes and the loss of nanotransporter during purification was observed.
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2.3. Labeling of CS NPs by AntiSar Antibodies
The scope was to design nanocarrier which can target into the cancer tissue with highly expressed
levels of sarcosine, such as prostate cancer. Non-specific conjugation of AntiSar antibody to Zn/CS
NPs surface was utilized. This interaction is mediated by electrostatic and hydrophobic interactions
between positively charged CS and proteins [39]. The interaction verification was employed to the dot
blot analysis as a rapid and precise immunochemical method. Polyclonal chicken AntiSar antibodies
as an anchor for targeting Zn/CS NPs/Dox was utilized. Monoclonal rabbit AntiChicken antibodies
labeled with gold nanoparticles (AuNPs) were used as secondary antibodies. Based on our previous
studies the AuNPs was employed as a detection system due to its peroxidase activity and ability to
oxidize TMB substrate accompanied by color reaction [40].
To confirm the binding of the AntiSar antibodies on the Zn/CS NPs surface the functionality of the
Chicken AntiSar and Rabbit AntiChicken antibodies labeled with AuNPs using the dot blot analysis
were tested. The ability of AuNPs aggregation which is visible as a purple dot on the membrane
was utilized. After initiation of the primary antibodies, the membrane surface was blocked by a
bovine serum albumin (BSA) to avoid false positive results. The dot blot analysis shows a positive
signal in a both cases; the control (rabbit AntiChicken IgG labeled with AuNP) and the binding of
both antibodies (chicken and rabbit antibodies) (Figure 6A). It could be assumed that the proposed
system is applicable and therefore, it can be proceeded with chitosan testing itself. The chicken AntiSar
antibodies were attached to the surface of Zn/CS NPs. The formation of this complex was confirmed
by the interaction with AuNPs labeled sarcosine (AuSar). Figure 6B shows a positive signal of the
control sample and a weakly colored dot of gold sarcosine, 200 µg/mL. Similar results were achieved
if the selected detection system is rabbit or AntiChicken antibodies labeled by AuNPs (Figure 6C).
The stronger interaction was occurred when primary rabbit AntiChicken antibodies were immobilized
on the membrane. Next, we proceeded to test the sandwich method. The Zn/CS NPs-AntiSar labeled
by rabbit AntiChicken-AuNPs showed the strong positive reaction (Figure 6D).
To quantify the detection signal, the method from the membrane to the microplate was transferred
which enabled the spectrophotometric detection. For this experimental purpose, magnetic Zn/CS NPs
were employed. This system allows us to purify the sample from unbounded parts of the complex.
Figure 6E,F show strong positive signal of Rabbit AntiChicken-AuNPs in the empty nanocarrier and
with Dox. The results confirm the functionality of the bound antibodies to the Zn/CS NPs in vitro.
In further experiment, we used ELISA system to study the interaction of AntiSar antibodies
and Zn/CS NPs. AuNPs show pseudoperoxidase activity, which leads to the oxidation of the TMB
substrate. Figure 7A illustrates the photometric detection of the AntiSar/Zn/CS NPs. The characteristic
absorbance spectrum of the ox/red TMB reaction Sar/Au is illustrated in Figure 7A(a). After 45 min
two absorbance maxima peaks at 375 and 650 nm could be observed. The absorbance maximum at
650 nm belongs to the product of the enzymatic reaction between AuNPs and TMB in the presence of
H2O2. Characteristic reaction time-dependent course is showed in Figure 7A(b). From the reaction
curve is obvious a rapid increase of absorbance (λ = 650 nm) after 20 s. From 30th second the slight
increase of the absorbance occurred and the reaction slowly goes down.
Each component of the reaction system has been analyzed. The dependence of gold nanoparticles
labeled sarcosine (Sar/Au) on the absorbance shows linear trend in the range from 0.9 to 250 ng/mL
with the R2 = 0.99 and regression equation y = 0.3542x + 0.0013 (Figure 7A(c)). Further to Au/Sar
analysis the peroxidase activity of the Sar/Au attached to Anti/Sar antibodies was also monitored.
The dependence of labeled Anti/Sar antibodies concentration on the absorbance showed a linear trend
over the range from 7.8 to 1000 µg/mL. The regression equation was found to be y = 3.8868x − 66.712
and R2 = 0.99 (Figure 7A(d)). The calculated concentration of Anti/Sar antibody was found to be
between 20 and 40% in the analyzed complex (chitosan signal was subtracted).
AuMNPs were used as a tool to immobilize the nanotransporter complex via magnet which
enable the purification of the NPs from the unbounded parts. The dependence of encapsulated
doxorubicin concentration on the fluorescence signal is shown in Figure 7A(e). The determined
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amount of encapsulated Dox in the Zn/CS NPs structure is in the range from 5 to 10%. Figure 7A(f)
shows the characteristic fluorescence spectra of Dox in the presence of Zn/CS NPs and AuMNPs.
Further, formation of the Zn/CS NP-antibody complex in ELISA system was proved. Two
detection schemes were designed for this purpose (a) using AuNPs labeled Anti/Sar Antibodies and
(b) using AuNPs labeled sarcosine (Sar/Au). After the TMB addition, the peroxidase activity was
evaluated in both cases (a,b) in the three parts of complex: 1—background presented as a Chicken
AntiSar antibodies, 2—control sample composed of AuNPs labeled sarcosine or AuNPs labeled AntiSar
antibodies and 3—whole complex. As is shown in Figure 7B(a,b), the highest signal occurs in the case
of formed complex Zn/CS NPs-AntiSar antibodies for both detection systems, in comparison with the
background. The control sample shows positive signal in both cases this could be attributed to the
functionality of the detection system.
Nanomaterials 2017, 7, 435    9 of 22 
 












T   quantify  the  detection  signal,  th   method  from  the  membrane  t   the  microplate  was 















unbounded  parts.  Concentration  of  used  AuNPs  for  sample  labeling  was  125 mg/mL,  chicken 
Figure 6. Dot blot assay of AntiSar/Zn/CS NPs. On the left side, all results from the control sample
are presented. (A) Testing the functionality of Chicken AntiSar and Rabbit AntiChicken IgG. As a
detection system, the AuNPs IgG was used. (B) Ability of CS NPs to bind Chicken AntiSar IgG. As a
detection system, the AuNPs labeled sarcosine was used. (C) AntiSar/Zn/CS NPs detection via Rabbit
AntiChicken IgG labeled with AuNP. Interaction of Rabbit A tiChicken IgG with (D) An Sar/Zn/CS
NPs, (E) AntiSar/Zn/CS NPs-AuMNPs and (F) AntiSar/Zn/CS NPs/Dox-AuMNPs detection via
Rabbit AntiChicken IgG labeled with AuNP. The principle of detection was the aggregation of AuNPs
after 20 min. All tested membranes were blocked by 1% BSA for 30 min in 22 ◦C and rotation 30 rpm.
Between each experimental step membranes were washed 3-times in 5 mL PBS-T, pH 7) to purify
the unbounded parts. Concentration of used AuNPs for sample labeling was 125 mg/mL, chicken
antibodies 30 mg/mL and antichicken antibodies 40 mg/mL. All experiments were carried out in
three replicates.
Finally, the binding ability of Zn/CS NPs with sarcosine was evaluated. On the polystyrene
surface, the Chicken AntiSar antibodies were immobilized and in the presence of sarcosine (1 mg/mL)
the Zn/CS NPs/AntiSar formed a sandwich as is demonstrated in the scheme in Figure 7B(b,c).
Low peroxidase activity is estimated in the case of background sample (bonded AntiSar antibodies).
Higher peroxidase activity signal of control sample signalized the presence of AuNPs labeled AntiSar
antibodies. Whole complex shows the highest peroxidase activity and confirm the function of Zn/CS
Nanomaterials 2017, 7, 435 11 of 22
NPs/AntiSar nanoparticles to bind sarcosine. From these unique results it could be concluded, that
our designed chitosan nanocarrier for doxorubicin (or other anthracycline antibiotic) is able to bind
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Figure 7. (A) Spectrophotometric characterization of AuNPs-AntiSar IgG pseudoperoxidase activity.
(a) Characteristic spectra of AuNPs peroxidase activity in the range of 300–800 nm. (b) Typical reaction
curve of AntiSa /Zn/CS AuNP nan particles. Amount of det ct d antibody in the complex was in
the range 0–4 %, the signal of CS was subtracted. (c) Depende of AuSar concentration (0, 0.002,
0.004, 0.008, 0.016, 0.03, 0.06, 0.1 and 0.25 mg/mL) on absorbance at 650 nm. (d) Dependence of signal
intensity at A650 on the chicken AntiSar antibody concentration (0, 1, 2, 4, 8, 16, 31, 66, 125, 250, 500 and
1000 µg/mL). (e) Dependence of signal intensity of Dox encapsulated into the AntiSar/Zn/CS NPs
nanotransporter (0, 1, 2, 4, 9, 18, 35, 70 and 140 ng/mL) and (f) characteristic doxorubicin fluorescence
spectra. Amount of bonded Dox was among 5–10%. (B) ELISA methodology of AntiSar/Zn/CS NPs
in various arrangements. (a) Left: scheme of experiment. AntiSar/CS NPs (complex) was bonded with
rabbit AntiChicken IgG (1 mg/mL) attach d on p lystyrene microplat . The detection was carried
out using pseudoperoxidase activity of Au-NPs/AntiChicken IgG. Right: peroxidase activity of each
tested samples: (1) control sample (2), bonded AntiSar antibody (3) complex. (b) Left: scheme of
experiment. AntiSar/Zn/CS NPs (complex) was bonded with rabbit AntiChicken IgG (1 mg/mL)
attached on polystyrene microplate. The detection was carried out using pseudoperoxidase activity of
Au-NPs/sarcosine. Left: peroxidase activity of each tested samples: (1) control sample (2), bonded
AntiSar a tibody (3) complex. (c) Left: scheme of experiment. AntiSar/Zn/CS NPs/Dox-AuMNPs
(complex) w s bonded to sarcosine (0–1 mg/mL) attache to rabbit AntiChicke IgG (1 mg/mL)
immobilized on polystyrene microplate. The detection was carried out using pseudoperoxidase activity
of Au-NPs/AntiChicken IgG. Right: peroxidase activity of each tested samples: (1) control sample (2),
bonded AntiSar antibody (3) complex. The reaction conditions were as follows: 0.05 mM TMB, 0.1 mM
acetate buffer pH 4 and 0.03% H2O2.
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2.4. Toxicity Evaluation of CS NPs
Hemolytic activity in human erythrocytes as an alternative to in vivo testing was used as a potential
screening method to evaluate CS NPs toxicity risk for intravenous administration. The impact of CS NPs
on human red blood cells (RBCs) lysis was carried out spectrophotometrically recording the absorbance
of hemoglobin at 570 nm. Each component of Zn/CS NPs have been investigated: CS, AuMNPs, Zn/CS
NPs-AuMNPs and AntiSar/Zn/CS NPs-AuMNPs (see in Figure 8). As a positive control, the deionized
water was used. From the results, it is obvious that the highest hemolytic activity shows unmodified
CS (67%). Interestingly, after CS NPs formation, the hemolytic activity decreased by 30% (Figure 8A).
This effect was similar in the case of Zn/CS NPs-AuMNPs and AntiSar/Zn/CS NPs-AuMNPs 40%
respectively 41%. These results suggested rather that TPP addition the formation of zinc stabilized
NPs leads to decrease CS toxicity and hemolytic activity. Our results are in good agreement with other
studies [41–43]. Several experimental data suggested the coating of NPs by PEG or hyaluronic acid reduce
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Figure  8.  Study  of  toxicity Zn/CS NPs/Dox‐AuMNPs.  (A) Determination  of hemolytic  activity  of 
prepared nanoparticles. The number of erythrocytes was 2.42 × 1012. Tested variants: water, CS (0.25 
mg/mL), AuMNPs (1 mg/mL), Zn/CS NPs/Dox‐AuMNPs (Dox = 6 μM) and AntiSar/Zn/CS NPs/Dox‐
AuMNPs  (Dox  =  6  μM).  Inset photographs of  each variant  (centrifugation  2000  rpm,  5 min.  to  a 
completely  clear  solution).  The  pellet  was  diluted  by  PBS.  The  supernatant  was 
spectrophotometrically analyzed, the absorbance spectra was obtained and the results were evaluated 
in 570 nm. Experiment was carried out using  two replicates.  (B) Toxicity evaluation of complexes 
using  eukaryotic  cells Saccharomyces  cerevisiae. Characteristic growth  curves  for CS  (0.25 mg/mL), 
AuMNPs  (1 mg/mL), Zn/CS NPs/Dox‐AuMNPs, AntiSar/Zn/CS NPs/Dox‐AuMNPs and Dox  (0.75 
μM).  (C) Average  inhibition effect of  samples:  (0) S.  cerevisiae,  (1) AuMNPs  (1 mg/mL),  (2) CS  (2 
mg/mL), (3) Zn/CS NPs/Dox‐AuMNPs (Dox 6 μM), (4) AntiSar/Zn/CS NPs/Dox‐AuMNPs (Dox 6 μM), 
Figure 8. Study of toxicity Zn/CS NPs/Dox-AuMNPs. (A) Determination of hemolytic activity of
prepared nanoparticles. The number of erythrocytes was 2.42 × 1012. Tested variants: water, CS
(0.25 mg/mL), AuMNPs (1 mg/mL), Zn/CS NPs/Dox-AuMNPs (Dox = 6 µM) and AntiSar/Zn/CS
NPs/Dox-AuMNPs (Dox = 6 µM). Inset photographs of each variant (centrifugation 2000 rpm,
5 min. to a completely clear solution). The pellet was diluted by PBS. The supernatant was
spectrophotometrically analyzed, the absorbance spectra was obtained and the results were evaluated
in 570 nm. Experiment was carried out using two replicates. (B) Toxicity evaluation of complexes using
eukaryotic cells Saccharomyces cerevisiae. Characteristic growth curves for CS (0.25 mg/mL), AuMNPs
(1 mg/mL), Zn/CS NPs/Dox-AuMNPs, AntiSar/Zn/CS NPs/Dox-AuMNPs and Dox (0.75 µM).
(C) Average inhibition effect of samples: (0) S. cerevisiae, (1) AuMNPs (1 mg/mL), (2) CS (2 mg/mL),
(3) Zn/CS NPs/Dox-AuMNPs (Dox 6 µM), (4) AntiSar/Zn/CS NPs/Dox-AuMNPs (Dox 6 µM), (5) Dox
(0.25 µM), (6) Dox (0.5 µM), (7) Dox (1 µM). Data are expressed as an average of 12 repetitions. See to
Materials and Methods Section for more information regarding experimental details.
The yeast has been widely used as a test organism, since it is nonpathogenic, simple and easy to
cultivate, has a fully annotated genome and shares a strong conservation at both metabolic and regulatory
levels, with experimentally less accessible eukaryotes [46]. The viability of S. cerevisiae in the presence
of main components of Zn/CS NPs (CS (2 mg/mL), AuMNPs (1 mg/mL), Zn/CS NPs-AuMNPs and
AntiSar/Zn/CS NPs-AuMNPs (Dox 6 µM)) and Dox (0.25, 0.5 and 1 µM) was tested. The viability was
determined as optical density at λ = 600 nm in time. From Figure 8B(a–e) is evident that the growth
phase of S. cerevisiae is causing absorbance increase and on the contrary, S. cerevisiae death is reflected
as optical density decrease (Figure 8B(a–e)). For the viability evaluation, the inhibitory effect of each
compound was determined. Figure 8C shows, the highest inhibitory effect up to 15% with doxorubicin
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(0.25, 0.5 and 1 µM) in contrary to both designs of Zn/CS NPs (Zn/CS NPs-AuMNPs and AntiSar/Zn/CS
NPs-AuMNPs) which showed the 3% inhibition effect. Surprisingly, CS alone and AuMNPs showed 6%
and 16% inhibition effect, respectively. Toxicity results proved the encapsulation of Dox to the chitosan
based nanotransporter had negligible effect on the S. cerevisiae.
3. Discussion
The preparation of chitosan nanotransporters that can deliver the drug to the damaged tissues
offers unquestionable benefits such as increasing the therapeutic window and reducing side effects.
Many methods for the study of chitosan nanoparticles have been employed [10,47–49]. Based on the
literature we applied ninhydrin assay for chitosan nanoparticle analysis [36]. For example, the ninhydrin
assay has been successfully used for the study of CS NPs interaction with ligands such as glycyrrhizin
and ferulic acid [50]. The decreased absorbance of Ruhemann’s purple indicated reduced amino group
content of chitosan nanoparticles which could be considered as an additional evidence of the successful
conjugation of selected ligands to the surface of chitosan nanoparticles [50]. Based on our results,
the ninhydrin assay allows not only interaction determination but could give a reliable data about
nanoparticle formation (see Figure 2). We supposed the relaxed structure of chitosan has an accessible
amino group for ninhydrin reaction. While the TPP is added to the structure is strongly crosslinked
and the nanoparticles are formed. The count of accessible amino groups decreases proportionally with
the level of crosslinking and the structure of formed nanoparticles. This change was monitored by
the decrease of the complex absorbance. Our results from ninhydrin assay determination of the CS
NPs formation are comparable with Gan et al. who proved the influence of TPP addition and CS NPs
formation using light scattering measurement [13]. In addition, our study was confirmed by independent
electrochemical approach which enables us to monitor CS NPs formation indirectly. Signal of the free zinc
ions is electrochemically detectable as reactions that deposit and dissolve metals [51,52].
[MLn]◦(solid) → e− + [MLn]+(solvated) stripping (1)
In the case of complex formation there is a shift in the observed signal but also a decrease in
electrochemical response and changes in mechanism of charge transfer.
[MLn]◦(solid) /CS→ e− + CS/[MLn]+(solvated) stripping (2)
In comparison with literature, zinc influence of Dox entrapment efficiency has minimal effect and
the encapsulation efficiency achieves similar level [53–56]. As Anitha et al. showed, the cargo release
efficiency from chitosan nanocarrier is pH dependent [57] and after rapid doxorubicin elimination
follows stable phase of the drug release [58]. The possibilities to modulate CS NPs for target therapy
have been published by many authors. e.g., folate [59], aptamers [60], herceptin [61] were successfully
bonded on the CS NPs surface. Antibody attachment and chitosan nanoparticle loading have been used
by other authors with very promising results [62–64]. In summary, this mechanism for targeting cancer
tissue is one of the most precise approaches to drug delivery nanosystems [26,65–67]. In addition,
many studies showed low toxicity of chitosan polymer. Unfortunately, the evaluation of nanoparticle
toxicity remains limited [68,69]. Our results confirmed the low toxicity of CS and also the low toxicity
of doxorubicin loaded CS NPs compared to doxorubicin alone. S. cerevisiae as a broadly used model
organism for anthracycline drug testing. Observations from other studies illustrate the higher resistance
of S. cerevisiae against doxorubicin and the protective effect of glutathione and or metallothioneins [70].
The assessment of the results should be considered the phase of the cell cycle, which has a direct effect
on the toxicity of doxorubicin [71–74]. Further investigations are necessary as well as a selective effect
on healthy and prostate tumor tissue.
The chitosan nanoparticles for doxorubicin delivery have been introduced by many authors [55].
Their popularity is given due to its good biocompatibility, possibilities for modifications, low cost
and easy to prepare protocols. Based on several studies, zinc combined with chitosan has several
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applications such as: sensors [75], micronutrient nanocarrier [76] and nanocomposite coatings [77–79].
In our pilot experiment, zinc ions were incorporated into the CS NPs structure for a purpose
of NP structure stabilization and passive targeting. The mechanism of stabilization could be
explained by involving the amino groups of chitosan in the binding of zinc ions as well as ionic
cross-linking with TPP molecules [76]. Although zinc is not used as a direct decoy for tumors in
nanopharmaceuticals, several studies have pointed out the enhanced uptake of zinc ions in prostate
cancer [80,81]. Normal prostate glands contain higher levels of zinc compared with cancerous tissues
as well as the levels of MT. Generally, MT binds zinc more tightly than most other zinc proteins
and constitutes a thermodynamic “sink” for zinc, in particular because the zinc concentration of
MT is relatively high in comparison with other zinc proteins. Moreover, zinc could play therapeutic
role in the cancer treatment. Jing et al. found that the zinc induces metallothionein overexpression
which prevents cardiomyocytes from doxorubicin toxicity [82] and the apoptotic effect of zinc on
malignant cells have been reviewed by Franklin et al. [83]. Additionally, MTs’ overexpression has
been linked to chemoresistance in carcinoma cells [76]. These studies indicate the positive effect of
zinc ions in the nanocarrier structure for doxorubicin delivery. Beside zinc, designed doxorubicin
nanotransporter utilize other mechanism for target delivery of doxorubicin via attached antibodies.
Generally, in conventional treatment the antibodies are oriented to specific receptors of malignant
cell [84–86]. This research area has been explored by several promising studies and the findings
are summarized in interesting reviews [87–89]. In fact, sarcosine is associated with glycine which is
essential precursor for the synthesis of proteins, nucleic acids and lipids that are crucial to cancer cell
growth [90]. Jain et al. showed that this metabolism of glycine could be used to target the rapidly
proliferating cancer cells [91], possibly becoming a new anti-cancer treatment [92]. Since metabolites
play an important role in tumor progression, it is necessary to study in detail. All the mechanisms,
combination therapy approaches of cancer diseases and passive targeting to the product of cancer
metabolism could improve the overall view of treatment of cancer diseases and gives a better chance
for survival this serious disease.
4. Materials and Methods
4.1. Chemicals
Low molecular weight chitosan, Sodium Tripolyphosphate penta basic (TPP), DMSO, Sodium
Acetate, Acetic acid, Doxorubicin HCl, Zinc Chloride, monoclonal Rabbit AntiChicken IgG and other
chemical unless noted otherwise were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ninhydrin,
hydrindatin were purchased from (Ingos, Prague, Czech Republic). Polyclonal Chicken AntiSarcosine
IgG was purchased from (Hena, Prague, Czech Republic). S. cerevisiae (ATCC 9763) were obtained from
the Czech Collection of Microorganisms, Faculty of Science, Masaryk University, Brno, Czech Republic.
Aqueous solutions for size analysis were prepared using PURELAB® Ultra (Elga, High Wycombe,
UK) resistivity 18 MΩ-cm. For other purposes deionized water was used.
4.2. Chitosan Nanoparticles Preparation
In the case of Zn inner type of CS NPs, 12.5 mg of low MW chitosan was dissolved in 5 mL of
1% acetic acid. Doxorubicin (30 µM) and zinc (0.5 m/mL) was added to the chitosan solution under
stirring, 30 rpm (3 h, 24 ◦C). After chitosan dissolution, the sodium tripolyphosphate (0.25% w/v)
was added dropwise and incubated (30 min, 22 ◦C, 30 rpm) in rotator Multi-Rotator RS-60 BIOSAN.
Zn outer type NPs were prepared in the same way, however the zinc (0.5 mg/mL) was added after
TPP gelation. The mixture was stirred (30 rpm, 3 h, 24 ◦C).
4.3. AuNPs Preparation and Sarcosine/IgG Labeling
Gold nanoparticles (AuNPs) were prepared by mixing of 10 mL HAuCl4·3H2O solution (1 mM)
and 250 µL C6H5Na3O7·2H2O (0.09 M). The mixture was stirred (30 rpm, 1 h in 20 ◦C) using magnetic
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stirrer (VMS-C4, VWR International s.r.o., Darmstadt, Germany). The light yellow solution turned to
purple and the AuNPs were formed.
Conjugation of AuNPs to sarcosine or IgG. 5 mL of AuNPs was added to 10 mL of 5 mM borate
buffer (pH 8.8) under stirring (VMS-C4, VWR International s.r.o., Darmstadt, Germany). Subsequently,
the 0.5 mL of Sar/IgG (1 mg/mL) was added dropwise. The mixture was incubated at 37 ◦C and at
350 rpm for 90 min (ThermoMixer F1.5, Eppendorf, Hamburg, Germany). Finally, the mixture was
centrifuged (14,000 rpm, 22 ◦C and 10 min) and the formed pellet was diluted in 1 mL of 5 mM borate
buffer. This step was repeated 4× times. After the last centrifugation, the pellet was dissolved in 2 mL
of storage buffer (10 mM borate buffer (pH 8.8), 1% BSA). Prepared samples were stored in 4 ◦C.
4.4. AuMNPs Preparation
1.5 g Fe(NO3)3·9H2O was dissolved in 80 mL water. 1.4 mL 25% NH3 was diluted in 8.6 mL water
and 0.2 g NaBH4 was dissolved in this mixture. Mixture was stirred (30 rpm, 10 min at 22 ◦C) and after
that the solution of Fe(NO3)3·9H2O was added. The color of solution turned to dark brown. The mixture
was heated up to 100 ◦C for 2 h and stirred (30 rpm, overnight at 100 ◦C). The magnetic particles were
separated from the solution via magnet and washed several times in water. The solution of HAuCl4
(25 mL, 1 mM) was added to the magnetic particles and stirred (30 rpm 1 h at 22 ◦C). Subsequently, the
solution of C6H5Na3O7·2H2O (0.75 mL, 0.265 g/10 mL) was added to the mixture and stirred overnight.
Finally, the gold magnetic nanoparticles (AuMNPs) were separated via magnet and dried (40 ◦C).
4.5. Ninyhdrin Assay for Chitosan Detection
The reaction solutions were then processed as described by [35,93]. The ninhydrin reagent was
freshly prepared on the day of the assay by adding 25 mL of 4 M acetate buffer (pH 5.2) to 2 g
ninhydrin and 0.3 g hydrindantin in 75 mL DMSO. For the assay, 75 µL of reagent was added to
100 µL of the sample in Eppendorf tube. The microtubes were immediately capped, briefly shaken by
hand and heated by thermoblock for 30 min to allow the reaction to proceed. After cooling, 15 mL
of a 50:50 ethanol:water mixture was added to each sample. The color intensity of the complex
was spectrophotometrically evaluated as a measure of depolymerized chitosan activity. Accurately
weighed depolymerized chitosan was dissolved in 1% w/v acetic acid. A blank solution was also
prepared in an identical manner, wherein 1% w/v acetic acid was used instead of a chitosan solution
to prepare the reaction mixture. The effect of the solvent system was mollified by calibrating the
instrument to 100% transmittance of the blank solution. Relative absorbance for each CS NPs solution
was calculated as follows:
RA = A of chitosan solution/A of standard solution (3)
4.6. Absorbance Measurements
Absorbance scan was carried out in the range from 300 to 700 nm by 2 nm steps. The samples for
measurements (100 µL) were placed in 96 well UV plate (IAB, Prague, Czech Republic). All measurements
were performed at 22 ◦C. (VWR, Darmstadt, Germany).
4.7. Fluorescence Reading
The fluorescence scan of doxorubicin was carried out using a fluorimeter (Infinite M200, TECAN,
Männedorf, Switzerland). Measurement conditions were as follows: emission wavelength 510–700 nm,
excitation wavelength 480 nm, gain 200, number of flashes 35, integrated time 50 µs. The samples for
measurements (100 µL) were placed in 96 well UV plate (IAB, Prague, Czech Republic).
4.8. Electrochemical Determination of Zinc Ions
Determination of Zn2+ by difference pulse voltammetry (DPV) was performed at 663 VA Stand
(Metrohm, Zofingen, Switzerland) connected with Analyzer (Metrohm). A hanging mercury drop
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electrode (HMDE) with a drop area of 0.4 mm2 was employed as the working electrode. An Ag/AgCl/3
M KCl electrode acted as the reference and platinum electrode was auxiliary. The analyzed samples
were deoxygenated prior to measurements by purging with argon (99.999%). Acetate buffer (0.2 M
sodium acetate and 0.2 acetic acid, pH = 5) was used as a supporting electrolyte. The parameters of the
measurement were as follows: initial potential 0 V, end potential −1.7 V, deoxygenating with argon
120 s, accumulation time 120 s, step potential 5 mV, modulation amplitude 25 mV, volume of injected
sample: 50 µL, volume of measurement cell 10 mL.
4.9. CS NPs Magnetic Separation
The CS NPs were prepared according to Section 4.6. 12.5 mg of low MW chitosan was dissolved
in 5 mL of 1% acetic acid. Doxorubicin (30 µM) and zinc (0.5 mg/mL) and AuMNPs (1 mg/mL)
were added to the chitosan solution under stirring (3 h, 24 ◦C). After chitosan dissolution, the sodium
tripolyphosphate (0.25% w/v) was added dropwise and incubated in rotator Multi-Rotator RS-60
BIOSAN. Magnetic AntiSar/Zn/CS NPs/Dox-AuMNPs was immobilized via magnet and washed
using PBS buffer prior to each analysis.
4.10. CS NPs-Dox Entrapment Efficiency
The entrapment efficiency (EE) of the CS NPs was expressed as the actual doxorubicin loading
of the NPs referred to the initial amount of doxorubicin used. The encapsulated Dox concentration
was calculated from the calibration curve of fluorescence signal. EE (%) was calculated using the
following equation:
EE (%) = amount of Dox in NPs/amount of initial Dox used × 100 (4)
4.11. Cumulative Release of Dox from CS NPs
100 µL of CS NPs/Dox-AuMNPs were added to 4 (1.5 mL) tubes (Eppendorf, Hamburg, Germany).
Into each tube 1–4 was added 500µL of 1 mM phosphate buffer pH 5, 6 and 8 or whole blood. Samples were
incubated on a rotator (Multi RS-60, Biosan, Latvia) for 30 min, 30 rpm 22 ◦C. Subsequently, the NPs were
immobilized via magnet and washed with 500 µL of 1% acetic acid. Finally, CSNPs/Dox-AuMNPs was
re-suspended in 300 µL of 1% acetic acid and transferred to the UV plate (IAB, Prague, Czech Republic).
The process was repeated until the end time of the analysis.
4.12. Dot Blot Assay
On the nitrocelulose membrane 0.45 µm pore diameter (SERVA, Heidelberg, Germany) was
pipetted 1–2 µL of Rabbit AntiChicken antibody (30 mg/mL). After drying, the membrane was
blocked by 1% BSA in PBS buffer. After 30 min incubation in the rotator the membrane was soaked in
the CSNPs (AntiSar/CS NPS/Dox-AuMNPs) solution for 1 h. The incubation was carried out in the
50 mL tube on rotator (15 rpm). The membrane was 3× washed using PBS-T. Further, the membrane
was soaked in AuNPs labeled antibody (40 mg/mL) or sarcosine (1 mg/mL) for 1 h. Each sample
was washed from unbounded parts by PBS-T buffer. After dying the membrane, the samples were
prepared for evaluation.
4.13. ELISA
AntiSarCS NPs/Dox immunodetection was tested by ELISA. Microtitration plate was coated
with 100 µL per well of primary (AntiChicken) antibody diluted 1:1000 in 0.05 M carbonate buffer
(32 mM Na2CO3 and 0.068 M NaHCO3, pH 9.6) at 37 ◦C for 1 h. After coating the free surface the
wells were blocked with 150 µL per well of 1% BSA (w/v) in PBS (137 mM NaCl, 2.7 mM KCl, 1.4 mM
NaH2PO4 and 4.3 mM Na2HPO4, pH 7.4) for 30 min at 37 ◦C, then the wells were washed 5× with
350 µL of 0.05% (v/v) PBS-T (Hydroflex, TECAN, Männedorf, Switzerland). Then, 100 µL of the
sample of AntiSar/CS NPs/Dox-AuMNPs were added and the microplate was incubated at 37 ◦C for
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1 h. After washing with PBS-T, 100 µL of secondary (AntiChicken) antibody AuNPs conjugated in
dilution 1:100 in PBS was added and the plate was incubated for 60 min at 37 ◦C. After incubation and
washing 100 µL of 0.45 mM TMB in 0.5 M acetate buffer adjusted to pH 4 with citric acid with 2.9%
(v/v) of H2O2 was added. The absorbance was read at 650 nm during 45 min with 5 min steps (Infinite
M200 Pro, TECAN, Männedorf, Switzerland).
4.14. Hemolytic Assay
Hemolytic assay was carried out on human erythrocytes. Plasma from the fresh blood sample
collected from a laboratory staff (RBC 5.16 × 1012 L; HBG 161 g/L; MCV 83.6 fl Hematology analyzer
Mindray BC-5500, Shenzhen, China) was removed by multiple washings with 150 mM sodium chloride
and centrifuged at 5000 rpm for 5 min. Then, prepared samples were mixed with the RBC and incubated
for 1 h at 37 ◦C. PBS and 0.1% 18 MΩwater was used as negative and positive control. After completion
of the incubation period, the cells were centrifuged and the absorbance of the supernatant containing








where At is the absorbance of the supernatant from samples incubated with the particles, Ac is the
absorbance of the supernatant from the negative control (PBS) and A100% is the absorbance of the
positive control supernatant.
4.15. Inhibition Assay
For the determination of growth curves the LB medium (trypton, yeast extract, NaCl) was used.
Cultivated microorganisms (S. scerevisiae) were diluted using LB media to the absorption 0.1 at 600 nm
before measurement. To each well was pipetted 250 µL of diluted S. cerevisiae and 50 µL of the
tested sample was added. As a control, the 300 µL of LB media was added to the separate well.
The measurement was carried out on the Tecan infinite 200 Pro Multifunctional Reader (TECAN,
Männedorf, Switzerland) at 600 nm for 18 h and 37 ◦C. The absorbance value was recorded after
30 min. Each sample was analyzed in five independent repetitions. The results were expressed as an
average value.
4.16. Data Treatment and Descriptive Statistics
The experimental work was carried out in using the three independent experiments. The analysis of
each sample was carried out 5 times. Obtained data are presented as an average value. No experimental
subjects were excluded from the proposed experimental studies. All the obtained data are stored in the
Ladys database. If possible, data was processed and evaluated mathematically and statistically in the
Ladys database. Photographs were processed using the ColorTest program, which assigns intensity to
the individual pixels of the studied image in the color area.
5. Conclusions
A detailed interaction study of chitosan nanotransporter, zinc ions and TPP has been performed.
The Zn2+ ion concentration shows the strong effect on crosslinking and coiling of CS NPs with the result
of better nanoparticle stabilization confirmed by ninhydrin assay and electrochemical determination.
The entrapment efficiency for doxorubicin of designed CS NPs was 20%. The highest drug release
from the CS nanocarrier appears after 120 min in the pH 5, 6, 8 and blood. Functionality and ability of
the AntiSar/CS NPs/Dox to bind on the sarcosine molecule was proved using dot blot analysis and
ELISA. Observed hemolytic activity of the nanotransporter was 40% and the 20% inhibition activity on
the experimental model of S. cerevisiae. Zn/CS nanotransporter for doxorubicin delivery showed good
stability, doxorubicin binding capacity and low toxicity. In this study, we have demonstrated a design of
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nanotransporter suitable for doxorubicin. Due to the independent analytical methods, the functionality
and non-toxicity have been confirmed. Our results indicate the suitability of nanocarrier for testing
in vitro on cancerous tissue cultures.
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